Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Recognition of specific antigen through the B-cell receptor (BCR) stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...